TP 9201
Code | Size | Price |
---|
TAR-T24896-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24896-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
TP 9201 is a platelet integrin alphaIIbbeta3 antagonist. It is a synthetic RGD-containing cyclic peptide.
CAS:
138297-15-1
Molecular Weight:
1136.27
Purity:
0.98
SMILES:
[H][C@@]12CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1ccc(OC)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(N)=O)NC(C)=O
References
Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997 Sep;28(9):1789-96. PubMed PMID: 9303027.
TP 9201. Drugs R D. 1999 May;1(5):390-1. PubMed PMID: 10566073.
Modi NB, Reynolds T, Baughman SA, Thomas DA, Paasch BD, Smith SY. Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with recombinant tissue-type plasminogen activator, heparin, and aspirin in beagles. J Cardiovasc Pharmacol. 1996 Jan;27(1):105-12. PubMed PMID: 8656642.
Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, del Zoppo GJ. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000 Jun;31(6):1402-09; discussion 1409-10. PubMed PMID: 10835463.